Molecular classification characteristics and clinicalpathological observation of breast medullary carcinoma

doi:10.3760/cma.j.issn.1673-422X.2014.02.018

Abstract

Abstract: Objective To explore the characteristics and clinical significance of molecular subtypes and immunophenotypes of breast medullary carcinoma (MC). Methods Molecular classification was performed in 29 specimens of MC and 180 middlehigh level invasive carcinomas of no specific type (NST) based on the expressions of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2) and Ki-67 with immunohistochemical method. The expressions of Ecadherin, P53, Ki-67 and CD57 in basallike subtype carcinoma of two groups and the clinicalpathological features were analyzed retrospectively. Results The basal-like subtype carcinoma accounted for 58.6% (17/29) and 12.2% (22/180) in MC and NST group respectively. There were no statistical differences in the expressions of Ecadherin, P53 and Ki-67 between the two groups of basallike subtype carcinoma (P＞0.05). The CD57 positive expression rates of the two groups were 88.2% (15/17) and 31.8% (7/22), and the difference was statistically significant (P=0.001). The lymph node metastasis rates were lower, and the distant metastasis rate was 23.5% (4/17) in MC group and 68.2% (15/22) in NST group, which showed statistical difference (P=0.01). Conclusion In breast tumor, MC is less common, and its histological grade is high, and basal-like subtype is in the majority. This subtype in MC shows better prognosis than other basallike subtype carcinomas and lymphocytes infiltration in the stroma may be an important factor.

Key words: Breast neoplasms, Carcinoma, medullary, Immunophenotyping, Immunohistochemistry

Yang Yongjun, Zhang Xiulin, Wang Zuojun, Liu Jingfeng. Molecular classification characteristics and clinicalpathological observation of breast medullary carcinoma[J]. Journal of International Oncology, 2014, 41(2): 140-143.

References

［1］ Lakhani SR, Ellis IO, Schnitt SJ, et al. WHO classification of tumors of the breast. World Health Organization classification of tumors［M］. 4th ed. Lyon: IARC Press, 2012. ［2］ Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypesdealing with the diversity of breast cancer: highlight of the St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011［J］. Ann Oncol, 2011, 22(8): 1736-1747. ［3］ Perou CM, Srlie T, Eisen MB, et al. Molecular portraits of human breast tumors［J］. Nature, 2000, 406(6797): 747-752. ［4］ Matkovic B, Juretic A, Separovic V, et al. Immunohistochemical analysis of ER, PR, HER2, CK5/6, p63 and EGFR antigen expression in medullary breast cancer［J］. Tumori, 2008, 94(6): 838844. ［5］ Cheang MC, Chia SK, Voduc KD, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer［J］. Natl Cancer Insc, 2009, 101(10): 736-750. ［6］ Whibley C, Pharoah PD, Hollstein M. p53 polymorphisms: cancer implications［J］. Nat Rev Cancer, 2009, 9(2): 95-107. ［7］ Harris L, Fritsche H, Mennel R, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer［J］. J Clin Oncol, 2007, 25(33): 5287-5312. ［8］ Calil LN, Igansi CN, Meurer L, et al. Chlamydia trachomatis and human papillomavirus coinfection: association with p16INK4a and Ki67 expression in biopsies of patients with preneoplastic and neoplastic lesions［J］. Braz J Infect Dis, 2011, 15(2): 126-131. ［9］ DialloDanebrock R, Ting E, Gluz O, et al. Protein expression profiling in highrisk breast cancer patients treated with highdose or conventional dosedense chemotherapy［J］. Clin Cancer Res, 2007, 13(2 Pt 1): 488-497. ［10］ RodríguezPinilla SM, Sarrió D, Honrado E, et al. Vimentin and laminin expression is associated with basallike phenotype in both sporadic and BRCA1associated breast carcinomas［J］. J Clin Pathol, 2007, 60(9): 1006-1012. ［11］ Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study［J］. JAMA, 2006, 295(21): 2492-2502. ［12］ CharafeJauffret E, Ginestier C, Monville F, et al. Gene expression profiling of breast cell lines identifies potential new basal markers［J］. Oncogene, 2006, 25 (15): 2273-2284. ［13］ Li X, Guo M, Mori E, et al. Activation of caspase3 in molt4 cells by apoptosisinducing nucleosides from CD57(+)HLADR(bright) natural suppressor cell line［J］. Biochem Biophys Res Commun, 2000, 268(2): 514-520.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang. Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion [J]. Journal of International Oncology, 2023, 50(2): 71-75.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.